Cullinan Therapeutics

In case you missed Sachs Associates’ Annual Oncology Innovation Forum, be sure to watch the full panel discussion, “New Endpoints for Early-Stage Oncology Companies” featuring Nadim Ahmed, President and CEO. #Sachs_OIF

This Pride Month, we want to thank our guest speakers from SpeakOUT Boston who joined us to share their personal stories and shed light on the challenges faced by LGBTQ+ individuals in the workplace. At Cullinan, we’re committed to cultivating an environment where everyone can feel seen, heard, and valued. As part of this commitment, we provide learning opportunities and support systems to enhance cultural competence and allyship within our organization and community. SpeakOUT reminded us that being an ally is not a noun, it’s a verb – our actions speak louder than words. We hope you will join us this Pride Month and beyond in taking action to ensure everyone in your community feels safe, supported, and celebrated for who they are. Happy Pride Month!

Team Cullinan was proud to participate in the 2024 Kendall Square Challenge earlier this month. Our team helped raise funds to support local nonprofit InnerCity Weightlifting (ICW). Thank you Kendall Square Association for hosting such a fun way to give back to our community! 

Today, on Juneteenth, as part of our ongoing efforts to support organizations in our local community, we are proud to share that we have once again made a contribution to We Got Us. This Boston-based student-led coalition is dedicated to increasing access to equitable healthcare, community-centered health education, and direct healing for Black communities.    We are committed to working towards a future where everyone has access to high-quality care, regardless of their race or socioeconomic status. We know that this work requires sustained effort and a willingness to listen, learn, and take action.  

One of our core company values is innovation without borders to develop novel therapies. On June 17, Jennifer Michaelson, our Chief Scientific Officer, will participate in a panel discussion on innovation in drug discovery as part of Longwood Healthcare Leaders’ #SpringMIT event.    Click to learn more about Spring MIT. 

CEO Nadim Ahmed caught up with Brad Loncar of BiotechTV at #ASCO24 to discuss data Cullinan presented at this year’s conference & strategic expansion into autoimmune diseases. Check out the interview and learn more about Cullinan’s strategy and pipeline: https://bit.ly/455o5LY

Join us today at 6:30 p.m. CT for our investor event at #ASCO24 where we will take a deep dive into new clinical data for CLN-619 and zipalertinib. A live webcast and recording will be available here: https://bit.ly/4bD5WHU

Today at #ASCO24, we will present the first clinical data for CLN-619, a novel anti-MICA/B antibody, in combination with a checkpoint inhibitor and updated monotherapy data from our Phase 1 study in patients with advanced solid tumors.     Join our poster presentation between 9 a.m. and 12 p.m. CT today. Learn more here: https://bit.ly/454ITmW

Today, we announced positive initial data in patients receiving zipalertinib after prior treatment with amivantamab enrolled in our pivotal Phase 2b REZILIENT1 clinical trial. Learn more here.

As Asian American and Pacific Islander (AAPI) Heritage Month draws to a close, we want to thank Dr. Yuan Liu, a neuroscientist, writer, photographer, and public lecturer, for joining us virtually to share an engaging presentation on Asian Art Across Cultures. Dr. Liu is a docent at the Smithsonian National Museum of Asian Art and shared fascinating examples from their collection to highlight the influence of cross-cultural contact on artistic expression. The Cullinan team enjoyed honoring AAPI heritage through the lens of art history with this special learning opportunity. #AAPIMonth